Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation

Eur J Pharmacol. 1985 Jun 7;112(2):195-202. doi: 10.1016/0014-2999(85)90496-0.

Abstract

The mechanism of action of endothelium-derived relaxant factor (EDRF) was studied using aortic strip preparations of the rabbit and a bioassay system of a rabbit coronary artery perfused in series with an intact aorta. Methylene blue (an inhibitor of guanylate cyclase) inhibited, and 2-O-propoxyphenyl-8-azapurine-6-one (MB22948, an inhibitor of cGMP phosphodiesterase) potentiated the vascular effects of EDRF whether these were due to its basal or to stimulated release. Infusion of these agents at different sites in the bioassay indicated that they act pharmacologically at the smooth muscle level and not on release of EDRF or by chemical interaction with EDRF. The data are consistent with the hypothesis that EDRF-induced relaxation is mediated by elevation of smooth muscle cGMP levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Blood Vessels / drug effects
  • Blood Vessels / physiology*
  • Cyclic GMP / physiology*
  • Endothelium / drug effects
  • Endothelium / physiology
  • In Vitro Techniques
  • Methylene Blue / pharmacology
  • Purinones / pharmacology
  • Rabbits
  • Vasodilation* / drug effects

Substances

  • Purinones
  • zaprinast
  • Cyclic GMP
  • Methylene Blue